Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Share-based Compensation (2019 - 2025)

aTYR PHARMA's Share-based Compensation history spans 7 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 56.75% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $5.0 million, up 67.18%, while the annual FY2025 figure was $5.0 million, 67.18% up from the prior year.
  • Share-based Compensation reached $1.2 million in Q4 2025 per ATYR's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.3 million in Q3 2025 to a low of $360000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $717700.0, with a median of $658500.0 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: decreased 14.89% in 2021, then soared 79.5% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $414000.0 in 2021, then skyrocketed by 46.14% to $605000.0 in 2022, then rose by 8.93% to $659000.0 in 2023, then rose by 16.84% to $770000.0 in 2024, then soared by 56.75% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Share-based Compensation are $1.2 million (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025).